News
IKT
2.110
-6.64%
-0.150
Q32 BIO INC - IWICKI RESIGNS TO FOCUS ON CEO ROLE AT INHIBIKASE THERAPEUTICS
Reuters · 1d ago
Weekly Report: what happened at IKT last week (0414-0418)?
Weekly Report · 6d ago
Inhibikase Therapeutics Advances PAH Treatment with New Leadership
TipRanks · 04/15 03:52
Inhibikase Therapeutics Appoints New Chief Financial Officer
TipRanks · 04/14 12:46
Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns
Dow Jones · 04/14 12:41
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise
Seeking Alpha · 04/14 12:19
INHIBIKASE THERAPEUTICS INC - APPOINTMENT OF DAVID MCINTYRE AS CHIEF FINANCIAL OFFICER, EFFECTIVE APRIL 14, 2025
Reuters · 04/14 12:02
Press Release: Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Dow Jones · 04/14 12:00
*Inhibikase Therapeutics Appoints David McIntyre Chief Fincl Officer >IKT
Dow Jones · 04/14 12:00
Weekly Report: what happened at IKT last week (0407-0411)?
Weekly Report · 04/14 09:43
Weekly Report: what happened at IKT last week (0331-0404)?
Weekly Report · 04/07 09:43
Weekly Report: what happened at IKT last week (0324-0328)?
Weekly Report · 03/31 09:46
HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral
Benzinga · 03/28 17:26
Inhibikase Therapeutics (IKT) Receives a Hold from H.C. Wainwright
TipRanks · 03/28 13:15
Inhibikase Therapeutics GAAP EPS of -$1.16
Seeking Alpha · 03/27 21:04
Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/27 20:56
Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate
Benzinga · 03/27 20:03
Press Release: Inhibikase Therapeutics Announces -2-
Dow Jones · 03/27 20:01
Press Release: Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Dow Jones · 03/27 20:01
Weekly Report: what happened at IKT last week (0317-0321)?
Weekly Report · 03/24 09:43
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).